Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
libre de droit/iStock via Getty Images
Arrowhead Pharmaceuticals (ARWR) on Sunday said its drug plozasiran sharply reduced triglyceride levels and acute pancreatitis events in two Phase 3 studies involving patients with severe hypertriglyceridemia.
The SHASTA-3 and SHASTA-4 trials met their primary endpoints and all prespecified secondary
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.